Viatris Inc. (NASDAQ:VTRS) and Opus Genetics, Inc. (NASDAQ:IRD) are waiting on the same decision. By October 17, the FDA is due to rule on MR-141, an eye drop known as phentolamine 0.75%, as a treatment for presbyopia, the age-related loss of near focus. The application leans on two successful late-stage trials, VEGA-2 and VEGA-3, and the same drug is already sold as Ryzumvi for reversing dilated pupils, so this is a label expansion rather than a brand-new molecule. The two companies share it: Opus developed the drug and earns royalties, while Viatris holds the rights to sell it worldwide under a 2022 deal. One approval, two very different payoffs.
What Approval Does for Each
Let’s start with the upsides. For Viatris, it is a small but useful win. The company is a giant generic-drug maker trying to shift toward higher-margin branded medicines, and a differentiated, approved eye drop with a worldwide sales force behind it would further increase its visibility. It would not move a $20 billion company much on day one, but it is the kind of margin-friendly launch the turnaround needs more of. For Opus, the stakes are far larger. Opus is a tiny $340 million gene-therapy company still years from meaningful revenue on its main pipeline. A commercialized, partner-funded royalty stream would bring real cash and de-risk its balance sheet, while proving its phentolamine platform can reach the market. The same approval is a footnote for one and a milestone for the other.
Tailwinds and Headwinds
The risks differ too. The shared one is the market itself: presbyopia affects a huge number of people, but eye-drop treatments for it have sold slowly so far, as many patients simply stick with glasses, so approval does not guarantee uptake. For Viatris, the bigger swing factors sit with cutting costs and paying down roughly $14.7 billion of debt, while fighting price erosion on its generics; MR-141 alone will not fix those, so the stock lives or dies on the broader turnaround. For Opus, the danger is concentration. As a micro-cap whose value rests on a handful of events, a rejection or a weak launch would hit hard, and given its size, even good news can swing the shares sharply.
DON’T MISS: 10 Stocks With Low Debt And Strong Free Cash Flow
The Bottom Line
So, the same eye drop offers two different bets. Viatris is the steadier, diversified way to own the outcome, where MR-141 is a bonus on top of a large business that will be judged mostly on its debt and cost cuts. The company also offers a dividend yield of 2.74%. Owing to its size, on the other hand, Opus has far more of its value riding on this single decision and the launch that follows. One gives you a small call option inside a big company while the other is close to a pure bet on the drug.
Looking for dividend stocks? Check out those that hedge funds favor.
Market Sentiment
According to Insider Monkey’s database, 63 hedge funds held Viatris Inc. at the end of the second quarter of 2026, up from 60 the quarter before, with the value of those stakes holding near $1.9 billion. Opus Genetics, Inc., a micro-cap with limited institutional coverage, had 22 holders, roughly flat with 23 the quarter before, though the value of those smaller positions edged higher to $0.15 billion.
If you want to see where else the smart money is going in the sector, here are the 10 Best Healthcare Stocks To Buy According To Hedge Funds.
READ NEXT: Equifax (EFX) vs. TransUnion (TRU): Which Beaten-Down Credit Bureau Is the Better Buy? and Public Storage (PSA) vs. Extra Space (EXR): Which Self-Storage REIT Is the Better Buy?
This article is originally published at Insider Monkey.
Hedge Fund Resource Center